Your Messages Inbox
Your Article Summary
See Latest ArticlesFDA Determines VYVANSE was Properly Granted Five-Year Market Exclusivity
Shire, 10/27/09
Shire plc, the global specialty biopharmaceutical company, announces that the Food and Drug Administration, following a thorough administrative review of governing statutory and regulatory standards and public comments, has affirmed its prior decision to grant five–year New Chemical Entity exclusivity to lisdexamfetamine dimesylate—currently marketed by Shire U.S. Inc. for the treatment of attention–deficit hyperactivity disorder under the name VYVANSE.
Today in Marketing/Media/ROI...keeping you current
Receive free subspecialty "5-minute updates" via email
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/24/09
Boston Scientific Announces FDA Clearance and CE Mark for WallFlex Fully Covered Esophageal Stent
Boston Scientific, 11/24/09
Medtronic Introduces 3D Recon Service to Enhance Endovascular Treatment of Aortic Aneurysms
Medtronic, 11/20/09
Today in Medical Devices/Products...keeping you current
Receive free subspecialty "5-minute updates" via email
Huntington Hill Installs Toshiba Aquilion Premium CT
Imaging Economics, 11/25/09
Chugai Revises Corporate Advertisement for First Time in Four Years
Chugai Pharmaceutical Co., 11/24/09
Baytubes carbon nanotubes in marine coatings help reduce frictional resistance
BayNews International, 11/24/09
Article Search
Sponsor